Ferroquine: A New Anti-Malarial Drug
Author Information
Author(s): Mombo-Ngoma Ghyslain, Supan Christian, Dal-Bianco Matthias P, Missinou Michel A, Matsiegui Pierre-Blaise, Ospina Salazar Carmen L, Issifou Saadou, Ter-Minassian Daniel, Ramharter Michael, Kombila Maryvonne, Kremsner Peter G, Lell Bertrand
Primary Institution: Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon
Hypothesis
Can ferroquine be safely administered to adults with asymptomatic Plasmodium falciparum infection?
Conclusion
Ferroquine was generally well-tolerated up to 1,600 mg as a single dose and up to 800 mg as a repeated dose.
Supporting Evidence
- 54 out of 66 patients experienced at least one adverse event.
- Adverse events were mainly gastrointestinal symptoms.
- No serious adverse events were reported during the trials.
- Ferroquine showed a favorable safety profile in both single and multiple dose studies.
- Participants were followed up for eight weeks after treatment.
Takeaway
Ferroquine is a new medicine that helps fight malaria and is mostly safe for people who don't feel sick.
Methodology
The study involved two Phase I trials with young male volunteers aged 18 to 45, assessing the safety and tolerability of ferroquine through single and multiple doses.
Limitations
The small number of participants limits the ability to draw significant conclusions about adverse events.
Participant Demographics
Asymptomatic male volunteers aged 18 to 45 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website